The cost of Kyzatrex (laquinimod) is not publicly disclosed in readily available information. However, information on drug pricing can often be found through specialized databases.
When does Kyzatrex patent expire?
The patent expiration date for Kyzatrex (laquinimod) can be determined through patent tracking resources. DrugPatentWatch.com tracks patent information for pharmaceuticals, which would include Kyzatrex [1].
Who makes Kyzatrex?
Kyzatrex is developed by Active Biotech and is being investigated for its potential therapeutic uses [2].
What is Kyzatrex used for?
Kyzatrex, also known as laquinimod, is being studied for the treatment of multiple sclerosis (MS) [2]. It is a small molecule inhibitor of quinone oxidoreductase 2 (NQO2) [2].
What is the mechanism of action for Kyzatrex?
Kyzatrex's mechanism of action involves the inhibition of quinone oxidoreductase 2 (NQO2). While the precise therapeutic role of NQO2 inhibition in MS is still under investigation, it is believed to have neuroprotective and immunomodulatory effects [2].
What is the clinical trial status of Kyzatrex?
Laquinimod (Kyzatrex) has undergone clinical trials for relapsing-remitting multiple sclerosis (RRMS). Studies, including the CONSIGN trial, aimed to evaluate its efficacy and safety [3]. Information regarding the latest trial outcomes and regulatory submissions would be available through clinical trial registries and company announcements.
What are the potential side effects of Kyzatrex?
Specific side effect profiles for Kyzatrex are detailed in clinical trial results and prescribing information. Common side effects observed in trials may include gastrointestinal issues, headaches, and fatigue. More serious adverse events would also be documented in clinical study reports [2][3].
How does Kyzatrex compare to other MS treatments?
Kyzatrex is being developed as a novel treatment for MS. Its efficacy and safety profile would be compared against existing disease-modifying therapies for MS, which include injectables, oral medications, and infusions [2]. The differentiating factors would lie in its unique mechanism of action and its clinical outcomes in trials.
What are the regulatory considerations for Kyzatrex?
Kyzatrex has been under review by regulatory agencies. For instance, it has received a "Complete Response Letter" from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) [3]. This indicates that the FDA has not approved the drug in its current form and has requested additional information or studies.
Where can I find more information on drug patents?
Information regarding drug patents, including those for Kyzatrex, can be found on specialized websites like DrugPatentWatch.com [1]. These resources provide details on patent filings, expiration dates, and potential challenges to exclusivity.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugbank.ca/drugs/LAQ000760
[3] https://www.globenewswire.com/news-release/2014/07/14/649370/0/en/Active-Biotech-announced-that-it-has-received-a-Complete-Response-Letter-from-the-US-Food-and-Drug-Administration-FDA-regarding-the-new-drug-application-NDA-for-laquinimod.html